Xero Agrees to Buy Melio in Deal Valued at $2.5 Billion
Today's must-reads:
• Xero buys Melio
• Virgin Australia CEO
• Calls to ban YouTube for kids
New Zealand-based software company Xero has agreed to buy Melio Payments for $2.5 billion in an effort to accelerate US revenue growth, confirming an earlier report by Bloomberg News.
Virgin Australia Chief Executive Officer Dave Emerson brushed away concerns the Middle East conflict will disrupt demand for travel. Emerson's comments came as the Bain Capital-backed carrier finally completed a A$685 million initial public offering.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
TechCrunch
30 minutes ago
- TechCrunch
Hacker used a voice phishing attack to steal Cisco customers' personal information
A cybercriminal tricked a Cisco representative into granting them access to steal the personal information of users, the company said on Tuesday. Cisco said it discovered the breach on July 24, blaming the incident on a voice phishing or 'vishing' call. The hackers accessed and exported 'a subset of basic profile information' from the database of a third party cloud-based customer relationship management (CRM) system, according to the company's disclosure. Cisco said that the stolen data included the customer's 'name, organization name, address, Cisco assigned user ID, email address, phone number, and account-related metadata,' such as the account creation date. The networking tech giant did not specify how many users were affected by the breach, and company spokespeople did not respond to that question when TechCrunch reached out on Tuesday. As Bleeping Computer noted, this breach could be another one in a string of attacks that targeted companies' Salesforce data, including U.S. insurance giant Allianz Life, luxury retailer Tiffany and Co., Australian airline Qantas, and others. Cisco is a known customer of Salesforce, according to the cloud giant.
Skift
30 minutes ago
- Skift
The Maldives Sees 9% Tourism Growth
The Maldives welcomed 1.29 million tourists by July 2025, marking a 9.5% increase year-on-year, with strong off-season growth. The Ministry of Tourism said the country welcomed 180,438 visitors in July alone, an 11.8% increase over July 2024. The average number of daily arrivals is now exceeding 6,000. 73% of the tourists are staying at resorts, but guesthouses now account for 22% of stays. This segment has seen notable growth in recent years, particularly among budget-conscious travelers and regional source markets. A further 2% of arrivals opted for hotels and liveaboard safari vessels, which cater to niche segments such as divers and marine-focused travelers. As of July 2025, China leads all inbound markets with 188,317 arrivals, up 14.6% year-on-year. Russia was up 11.8% to 152,385 tourists, and the UK is in third place with 120,937 visitors, up 9.4%. The Maldivian government has set an ambitious target of reaching 2.5 million arrivals by the end of 2025, which woul
Yahoo
36 minutes ago
- Yahoo
Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alfa in Head and Neck Cancer with CPS <1
SYDNEY, AUSTRALIA, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ('Immutep' or 'the Company'), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces it has received positive and constructive feedback from the US Food and Drug Administration (FDA), regarding future clinical development of its first-in-class MHC Class II agonist, eftilagimod alfa ('efti'), for first line treatment of recurrent/metastatic head and neck squamous cell carcinoma (1L HNSCC) patients who have PD-L1 expression below 1 (Combined Positive Score [CPS] <1). Based on its review of the encouraging data in 1L HNSCC with CPS <1 from the TACTI-003 (KEYNOTE-C34) Phase IIb trial evaluating efti in combination with MSD's (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 KEYTRUDA® (pembrolizumab), the FDA agreed on the potential of efti in combination with KEYTRUDA to address the high unmet need in this CPS <1 patient segment and is supportive of the combination's further development. Paths for future clinical development and potential accelerated approval in light of the FDA's Project FrontRunner include a randomised registrational trial evaluating efti in combination with KEYTRUDA against standard-of-care therapy or alternatively a smaller single-arm study (e.g. 70 - 90 patients) with safety, response rate, and duration of response as key endpoints, followed by a confirmatory randomised study that builds on the existing data. 'We are pleased with the FDA's feedback and guidance that underscores the high unmet need of head and neck cancer patients whose PD-L1 expression level is below one. The FDA feedback positions Immutep to evaluate options for future collaborative clinical development paths to bring a new, effective and safe treatment option to this underserved patient population,' said Marc Voigt, CEO of Immutep. 'Our primary focus clearly remains the pivotal TACTI-004 Phase III evaluating efti as first line therapy for non-small cell lung cancer and we are excited with its progress to date and the consistent, encouraging feedback we hear from physicians. This focus and additional considerations will be reviewed internally and discussed with stakeholders and potential strategic partners in regards to forward paths in head and neck cancer,' added Mr Voigt. Project FrontRunner is an FDA Oncology Center of Excellence (OCE) initiative to encourage drug sponsors to consider when it may be appropriate to develop and seek approval of cancer drugs for advanced/metastatic disease, in an earlier clinical setting rather than the usual approach to develop and seek approval of a drug for treatment of patients who have received numerous prior lines of therapies or have exhausted available treatment options. In this setting, advancing new effective therapies has the greatest potential to significantly improve quantity and quality of patients' lives. Patients with CPS <1 in 1L HNSCC represent a treatment population with high unmet medical need. Up to 20% of 1L HNSCC patients have CPS <1 and despite immunotherapy's progress in fighting cancer, anti-PD-1 therapy alone (without chemotherapy) is only approved for patients who express PD-L1 (CPS >1). All currently available treatment options for patients with PD-L1 CPS <1 include chemotherapy. About Immutep Immutep is a late-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3's ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. Australian Investors/Media:Eleanor Pearson, Sodali & Co.+61 2 9066 4071; U.S. Investors/Media:Chris Basta, VP, Investor Relations and Corporate Communications+1 (631) 318 4000;
